Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,330
  • Today's Change7.00 / 0.53%
  • Shares traded129.03k
  • 1 Year change36.69%
  • Beta0.2543
Data delayed at least 15 minutes, as of Jul 29 2016 17:43 BST.
More ▼

Key statistics

Dechra Pharmaceuticals PLC (DPH:LSE) set a new 52-week high during Friday's trading session when it reached 1,333. Over this period, the share price is up 36.34%.
52-week range
Today
811.00Jun 24 20161,333Jul 29 2016
Markit short selling activity
Low
Med
High
Open1,333
High1,333
Low1,312
Bid1,330
Offer1,331
Previous close1,323
Average volume160.16k
Shares outstanding92.75m
Free float90.65m
P/E (TTM)57.96
Market cap1.23bn GBP
EPS (TTM)0.2295 GBP
Annual div (IAD)19.30 GBX
Annual div yield (IAD)1.45%
Div ex-dateMar 10 2016
Div pay-dateApr 06 2016
Data delayed at least 15 minutes, as of Jul 29 2016 17:43 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Dechra Pharmaceuticals PLC shares was Buy at 1,047 on 16 Jun 2016Read the full article

Board of Directors

1/8

Michael Redmond: Non-Executive Chairman

2/8

Ian Page: Chief Executive Officer

3/8

Anne-Francoise Nesmes: Chief Financial Officer

4/8

Tony Griffin: Managing Director, Dechra Veterinary Products EU

5/8

Ishbel Macpherson: Senior Independent Non-Executive Director

6/8

Dr Christopher Richards: Non-Executive Director

7/8

Julian Heslop: Non-Executive Director

8/8

Zoe Goulding: Company Secretary and Solicitor

Preliminary Results for year ended 30 June 2014

Half Year Financial Report 2015

© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.